PharmaCyte Biotech, Inc. (PMCB) Stock Score, Valuation & Financial Research
PharmaCyte Biotech, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for PMCB
PharmaCyte Biotech, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.41. These figures are a research snapshot, not a buy or sell recommendation.
What PharmaCyte Biotech, Inc. does
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.
Company business and revenue
Research reporting period: 2026-04-30. A research update is not a new financial filing.
How the company makes money
PharmaCyte Biotech is a biotechnology company focused on the development and commercialization of cellular therapies for cancer. The company utilizes its proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box, to develop product candidates such as CypCaps, and currently generates no revenue as it remains in the research and development stage.
Products and services
- The company's primary product candidate is CypCaps, a cellular therapy for cancer based on the proprietary Cell-in-a-Box live cell encapsulation technology.
Brands and product families
- Cell-in-a-Box — Proprietary live cell encapsulation technology platform. Source
- CypCaps — Current generation product candidate utilizing the Cell-in-a-Box technology. Source
Suppliers, materials and equipment
- Contract Research Organizations and Clinical Trial Sites — The company relies on third-party service providers for clinical trial management and manufacturing support; specific supplier names are not disclosed. Source
Business relationships and partnerships
- SG Austria — A collaborative partner involved in the encapsulation of cells and testing of delivery mechanisms such as glide force and pressure testing for syringes and catheters. Source
Business strengths to evaluate
- Proprietary Cell-in-a-Box live cell encapsulation technology Source
Business risks and research considerations
- History of operating losses and lack of revenue Source
- Dependence on clinical trial success and regulatory approval Source
Sources: Company research source
Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
PMCB financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 0.41
- Market capitalization:
- 4.38M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -16.15M
- Free cash flow:
- USD -5.15M
- Cash:
- USD 17.74M
- Total debt:
- USD 0.00
- EPS:
- USD -2.41
What stands out
- Free cash flow is USD -5.15M, negative for the stored period.
- The balance sheet shows USD 17.74M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 17.74M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for PMCB
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can PMCB fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is PMCB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for PMCB to reach sustainable profitability?
- What does the current fundamental change risk warning mean for the reliability or interpretation of PMCB's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-01.
Research-input completeness: 64% of the scoring inputs required for this public page are currently available.
How to research PMCB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.